
Peptide Analogs
Lyophilized 10 mg vial of retatrutide, a synthetic multi-receptor peptide agonist analog studied in metabolic research contexts. Supplied as a reference standard for analytical and laboratory research use only.
Sequence
Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Leu-Leu-Asp-Lys-Lys-Ala-Gln-{Ξ±MeLeu}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NHβ
Potency
10 mg vial
SKU
RET-10MG
Lead time
2 business days
Shelf life
24 months
Compliance
Select dose
$96.00per vial
Volume discounts
6 available
Products will arrive in a lyophilized (powder) form for maximum stability during shipping.
| Properties | |
|---|---|
| XLogP3 | β6.3 |
| PubChem LCSS | PubChem LCSS β View on PubChem β |
| Classification | Modified peptide (lipidated) |
| Molecular Formula | CβββHβββNββOββ |
| Monoisotopic Mass | 4728.4718 |
| Rotatable Bond Count | 159 |
| Average Molecular Weight | 4731.34 g/mol |
| Hydrogen Bond Donor Count | 58 |
| Hydrogen Bond Acceptor Count | 70 |
| Identifiers | |
|---|---|
| CAS | 2381089-83-2 |
| CID | 171390338 |
| UNII | NOP2Y096GV |
| InChI | InChI=1S/C221H342N46O68/c1-23-124(11)179(208(322)241-144(83-88-176(291)292)192(306)245-150(105-134-69-75-137(276)76-70-134)196(310)244-148(100-121(5)6)194(308)243-147(99-120(3)4)193(307)240-142(82-87-175(289)290)187(301)230-110-169(282)229-113-173(286)264-92-51-61-161(264)206(320)253-158(116-270)203(317)251-157(115-269)189(303)232-111-170(283)233-128(15)212(326)266-94-53-63-163(266)214(328)267-95-54-64-164(267)213(327)265-93-52-62-162(265)207(321)250-156(114-268)183(226)297)258-200(314)152(103-131-55-41-39-42-56-131)242-185(299)127(14)235-216(331)219(18,19)262-205(319)145(80-85-166(225)279)237-184(298)126(13)234-190(304)140(60-48-50-90-227-172(285)119-335-98-97-334-96-91-228-167(280)86-81-146(215(329)330)236-168(281)65-45-37-35-33-31-29-27-25-26-28-30-32-34-36-38-46-66-174(287)288)238-191(305)141(59-47-49-89-222)239-198(312)154(107-177(293)294)247-195(309)149(101-122(7)8)256-218(333)221(22,109-123(9)10)263-211(325)180(125(12)24-2)259-204(318)160(118-272)252-197(311)151(106-135-71-77-138(277)78-72-135)246-199(313)155(108-178(295)296)248-202(316)159(117-271)254-210(324)182(130(17)274)260-201(315)153(104-132-57-43-40-44-58-132)249-209(323)181(129(16)273)257-171(284)112-231-188(302)143(79-84-165(224)278)255-217(332)220(20,21)261-186(300)139(223)102-133-67-73-136(275)74-68-133/h39-44,55-58,67-78,120-130,139-164,179-182,268-277H,23-38,45-54,59-66,79-119,222-223H2,1-22H3,(H2,224,278)(H2,225,279)(H2,226,297)(H,227,285)(H,228,280)(H,229,282)(H,230,301)(H,231,302)(H,232,303)(H,233,283)(H,234,304)(H,235,331)(H,236,281)(H,237,298)(H,238,305)(H,239,312)(H,240,307)(H,241,322)(H,242,299)(H,243,308)(H,244,310)(H,245,306)(H,246,313)(H,247,309)(H,248,316)(H,249,323)(H,250,321)(H,251,317)(H,252,311)(H,253,320)(H,254,324)(H,255,332)(H,256,333)(H,257,284)(H,258,314)(H,259,318)(H,260,315)(H,261,300)(H,262,319)(H,263,325)(H,287,288)(H,289,290)(H,291,292)(H,293,294)(H,295,296)(H,329,330)/t124-,125-,126-,127-,128-,129+,130+,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,179?,180?,181-,182-,221+/m0/s1 |
| InChIKey | MLOLQJNKXBNWFW-SAGGEDDASA-N |
| DrugBank ID | DB18993 |
The material in this report is compiled for informational and educational discussion of the scientific literature and public database records. Retatrutide is an investigational compound studied in controlled research settings. For Laboratory Research Only. Not for human use, medical use, diagnostic use, or veterinary use. The U.S. Food and Drug Administration notes that UNII availability does not imply regulatory review or approval.
For Laboratory Research Only. Not for human use, medical use, diagnostic use, or veterinary use.